Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans

被引:131
作者
Fischer, CP
Perstrup, LP
Berntsen, A
Eskildsen, P
Pedersen, BK
机构
[1] Univ Copenhagen, Ctr Inflammat & Metab, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen, Fac Hlth Sci, DK-2100 Copenhagen, Denmark
[4] Roskilde Cty Psychiat Hosp Fjorden, Dept Med 3, Koge, Denmark
关键词
cytokines; epidemiology; inflammation; insulin resistance; type; 2; diabetes; obesity;
D O I
10.1016/j.clim.2005.07.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Elevated plasma IL-18 is present in several conditions sharing insulin-resistance as common trait, but the association with insulin-resistance per se is not established. Plasma/serum IL-6, IL-18, TNF-alpha, soluble TNF receptor 11 (sTNFR2), and C-reactive protein (CRP) were measured in 97 patients with type 2 diabetes (DM) and 84 non-diabetic controls (CON). The association with insulin-resistance-estimated using the homeostasis model assessment (HOMA-IR)-was analyzed using multivariate linear and logistic regression. Compared to CON, DM demonstrated higher plasma levels of IL-18 (P=0.001), IL-6 (P < 0.001), sTNFR2 (P=0.005), and CRP (P < 0.001), while TNF-a was lower (P=0.017). Plasma IL-18 increased across HOMA-IR quartiles in both DM and CON, both with and without adjustment for confounders (all P < 0.05). In contrast, neither IL-6, TNF-alpha, sTNFR2, nor CRP was associated with HOMA-IR in CON when adjusting for confounders. Accordingly, 50% increase of IL-18 corresponded to a marked increase of HOMA-IR in both DM and CON (DM: 26%, P=0.014; CON: 25%, P=0.003) after adjustment for confounders. Our results show that plasma IL-18 was associated with HOMA-IR independent of obesity and type 2 diabetes. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 160
页数:9
相关论文
共 48 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]   Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes [J].
Aso, Y ;
Okumura, K ;
Takebayashi, K ;
Wakabayashi, S ;
Inukai, T .
DIABETES CARE, 2003, 26 (09) :2622-2627
[4]   Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].
Blankenberg, S ;
Tiret, L ;
Bickel, C ;
Peetz, D ;
Cambien, F ;
Meyer, J ;
Rupprecht, HJ .
CIRCULATION, 2002, 106 (01) :24-30
[5]   Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes:: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness [J].
Carey, AL ;
Bruce, CR ;
Sacchetti, M ;
Anderson, MJ ;
Olsen, DB ;
Saltin, B ;
Hawley, JA ;
Febbraio, MA .
DIABETOLOGIA, 2004, 47 (06) :1029-1037
[6]   Overview of interleukin-18:: more than an interferon-γ inducing factor [J].
Dinarello, CA ;
Novick, D ;
Puren, AJ ;
Fantuzzi, G ;
Shapiro, L ;
Mühl, H ;
Yoon, DY ;
Reznikov, LL ;
Kim, SH ;
Rubinstein, M .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (06) :658-664
[7]   IL-18:: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family [J].
Dinarello, CA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) :11-24
[8]  
Dinarello CA, 2001, ANN RHEUM DIS, V60, pIII18
[9]   SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice [J].
Emanuelli, B ;
Peraldi, P ;
Filloux, C ;
Chavey, C ;
Freidinger, K ;
Hilton, DJ ;
Hotamisligil, GS ;
Van Obberghen, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) :47944-47949
[10]   Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome:: Relationship to insulin resistance and to obesity [J].
Escobar-Morreale, HF ;
Botella-Carretero, JI ;
Villuendas, G ;
Sancho, J ;
San Millán, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :806-811